文献速递心血管US

TRISCEND II:经导管三尖瓣置换术后1年右心重构与功能的超声心动图结果

TRISCEND II: Effect of Transcatheter Tricuspid Valve Replacement on Echocardiographic Measures of Right Heart Remodeling and Function.
PubMed 文献 · JACC Cardiovasc Imaging · 2026-07-18

TRISCEND II为多中心前瞻性随机试验,纳入400例重度有症状三尖瓣反流患者,按2:1随机分配至经导管三尖瓣置换术或药物治疗。术后1年超声心动图显示,TTVR组95.3%达到轻度反流,而下腔静脉直径、右室舒张期内径及右室收缩功能变化提示前负荷降低,右心室重构逆转,前向每搏量与心输出量显著增加。

要点

  • TTVR术后95%以上重度三尖瓣反流患者可在出院及1年时降至轻度反流。
  • 术后右室舒张期内径缩小伴收缩功能指标下降,反映前负荷降低而非心肌损伤。
  • 右室每搏量和心输出量显著增加,提示前向血流改善。

核心结论

  • TTVR术后1年三尖瓣反流接近消除,与静脉淤血减轻、右室逆重构及前向每搏量和心输出量显著改善相关。

研究设计与样本

  • 多中心、前瞻性随机试验,纳入400例重度有症状三尖瓣反流患者,按2:1随机分配至TTVR组267例或药物对照组133例。
  • 超声心动图由独立超声核心实验室统一评估。
  • 次要超声终点为三尖瓣反流严重程度从基线至出院时的降低。

关键影像表现/征象

  • 所有患者基线均为重度三尖瓣反流,出院时TTVR组95.5%为轻度反流。
  • 基线至1年配对分析中,TTVR组95.3%达到轻度反流,对照组为2.3%。
  • 基线至1年,TTVR组下腔静脉平均直径下降更显著(平静呼吸P<0.001,用力吸气P=0.038)。
  • TTVR组右室舒张期内径改善更大(P<0.05),右室收缩功能指标下降更大(P<0.001)。
  • 右室每搏量和心输出量在TTVR组显著增加(P<0.001),对照组无显著变化。

诊断标准与关键数值

  • 出院时轻度三尖瓣反流比例:TTVR组95.5%。
  • 1年时轻度三尖瓣反流比例:TTVR组95.3%,对照组2.3%。
  • 下腔静脉平均直径基线至1年变化:TTVR组下降更显著(平静呼吸P<0.001,用力吸气P=0.038)。
  • 右室舒张期内径改善:TTVR组优于对照组(P<0.05)。
  • 右室每搏量和心输出量增加:TTVR组P<0.001,对照组无显著变化。

临床应用与阅片要点

  • 超声随访TTVR患者时优先报告反流分级、下腔静脉直径及右室内径变化,以评估前负荷降低效果。
  • 术后右室收缩功能指标下降需结合内径缩小和前向每搏量增加解读,避免误判为心肌损伤。
  • 如术后右室每搏量或心输出量未见增加,应排查残余反流或其他影响前向血流的因素。

局限性

  • 原文摘要未报告右室收缩功能具体测量指标、盲法设计细节及长期随访数据。
  • 原文摘要未提供下腔静脉直径、右室内径及右室功能参数的绝对数值,仅有P值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: The TRISCEND II (EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy Using a Novel Device) trial demonstrated clinical benefits for transcatheter tricuspid valve replacement (TTVR) with the EVOQUE System over medical therapy for the primary safety and effectiveness endpoint to 1 year.

OBJECTIVES: The authors report echocardiographic outcomes at 1 year for the randomized cohort and evaluate hemodynamic and structural changes.

METHODS: The multicenter, prospective TRISCEND II trial enrolled 400 patients with severe, symptomatic tricuspid regurgitation (TR) and randomized them in a 2:1 ratio to TTVR (n = 267) or medical therapy (control) (n = 133). The secondary echocardiographic endpoint was reduction in TR severity from baseline to discharge. Echocardiograms were evaluated by an independent echocardiographic core laboratory.

RESULTS: All patients had severe TR at baseline; at discharge, 95.5% of patients who underwent TTVR had mild TR. On paired analysis from baseline to 1 year, 95.3% of patients who underwent TTVR and 2.3% of control patients achieved mild TR. Between baseline and 1 year, the mean inferior vena cava diameter decreased significantly more for patients who underwent TTVR (normal breathing P < 0.001; forced inhalation P = 0.038). Patients who underwent TTVR experienced greater improvements in diastolic right ventricular (RV) size (P < 0.05) and larger decreases in RV systolic function (P < 0.001), consistent with reduced preload from TR reduction. RV stroke volume and cardiac output increased significantly in patients who underwent TTVR (P < 0.001) but not in control patients.

CONCLUSIONS: One-year echocardiographic outcomes from the TRISCEND II trial demonstrated that near elimination of TR following TTVR is associated with reduced venous congestion, RV reverse remodeling, and significant improvements in forward stroke volume and cardiac output. (EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy Using a Novel Device [TRISCEND II Pivotal Trial]; NCT04482062).

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Sannino, Grayburn, Kodali, et al. TRISCEND II: Effect of Transcatheter Tricuspid Valve Replacement on Echocardiographic Measures of Right Heart Remodeling and Function. JACC Cardiovasc Imaging. 2026. PMID: 42470411. doi:10.1016/j.jcmg.2026.05.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。